DR causes heart failure

Article

Diabetic retinopathy (DR) is an independent risk factor for heart failure (HF), according to a study published in the April 22 2008 issue of the Journal of the American College of Cardiology.

Diabetic retinopathy (DR) is an independent risk factor for heart failure (HF), according to a study published in the April 22 2008 issue of the Journal of the American College of Cardiology.

Ning Cheung, MBBS of the Centre for Eye Research Australia at the University of Melbourne and colleagues conducted a ten-year retrospective population study of 1021 subjects. At baseline, all subjects had type 2 diabetes; none had renal complications, clinical coronary heart disease or HF; 12.8% of patients (n=125) had pre-existing DR.

At the nine-year follow-up, 10.1% of subjects (n=106) had developed HF. DR and non-DR subjects had different likelihoods of HF development: 21.6% and 8.5%, respectively. After adjusting for traditional HF risk factors, DR subjects were 2.5 times more likely than non-DR subjects to develop HF.

The researchers concluded that DR, and potentially other microvascular diseases, may play a prominent role in the pathogenesis of HF.

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.